FDA panel: Benefit of Baxter's immune therapy outweighs risk
(Reuters) - The benefits associated with Baxter International Inc's experimental treatment for certain diseases of the immune system outweigh the risks, an advisory committee to the U.S. Food and Drug Administration concluded on Thursday, paving the way for approval of the therapy.
The panel voted 15-1 that the available data show a favorable benefit to risk ratio for treatment, HyQvia, which is designed to treat primary immunodeficiency diseases.
These are genetic disorders in which certain cells of the immune system are missing, leading to a infections, recurrent pneumonia and abscesses of the organs.
The FDA is not obliged to follow the advice of its advisory panels but typically does so.
- U.S. pledges 3,000 troops to fight Ebola; experts say more needed
- Tesla prevails in top Massachusetts court over direct sales
- Russia needs government investment to avoid recession, says former finance minister
- Ahead of independence vote, Britain pledges state funding to Scotland |
- Stocks turn higher ahead of Fed meeting, oil up
Major U.S. poultry firms are administering antibiotics to their flocks far more pervasively than regulators realize, posing a potential risk to human health. Full Article